申请人:Hoffmann-La Roche Inc.
公开号:US05011849A1
公开(公告)日:1991-04-30
Ethylenediamine monoamides of the formula R--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2 I wherein R is one of groups ##STR1## in which R.sup.1 is phenyl monohalophenyl, monolower-alkylphenyl, monolower-alkoxypheynl, monotrifluoromethylphenyl, monocyanophenyl or monoaryl-lower-alkoxyphenyl, dihalophenyl, furyl, thienyl or monohalothienyl, R.sup.2 is hydrogen, halogen or amino, R.sup.3, R.sup.5 and R.sup.7 each are phenyl, monohalophenyl, dihalophenyl, thienyl, furyl or monohalofuryl, R.sup.4 and R.sup.6 each are hydrogen or amino and R.sup.8 is hydrogen or lower-alkyl, as well as their pharmaceutically usable acid addition salts are disclosed. The compounds have monoamine oxidase inhibiting properties with low toxicity and are useful for the treatment of depressive states and cognitive disorders.
公开了具有单胺氧化酶抑制性能且具有低毒性的乙二胺单酰胺化合物,其化学式为R--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2,其中R是下列基团之一:##STR1## 其中R.sup.1为苯基、单卤苯基、单较低烷基苯基、单较低烷氧基苯基、单三氟甲基苯基、单氰基苯基或单芳基-较低烷氧基苯基、双卤苯基、呋喃基、噻吩基或单卤噻吩基,R.sup.2为氢、卤素或氨基,R.sup.3、R.sup.5和R.sup.7各自为苯基、单卤苯基、双卤苯基、噻吩基、呋喃基或单卤呋喃基,R.sup.4和R.sup.6各自为氢或氨基,R.sup.8为氢或较低烷基,以及它们的药用可用酸盐。这些化合物具有单胺氧化酶抑制性能,低毒性,可用于治疗抑郁状态和认知障碍。